Literature DB >> 33384324

The Australasian Radiopharmaceutical Trials Network: Clinical Trials, Evidence, and Opportunity.

Roslyn J Francis1, Dale L Bailey2, Michael S Hofman3, Andrew M Scott4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33384324      PMCID： PMC8729868          DOI： 10.2967/jnumed.120.258152

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  7 in total

1.  Quantitative PET/CT scanner performance characterization based upon the society of nuclear medicine and molecular imaging clinical trials network oncology clinical simulator phantom.

Authors:  John J Sunderland; Paul E Christian
Journal:  J Nucl Med       Date:  2014-12-18       Impact factor: 10.057

2.  Accuracy of Dose Calibrators for 68Ga PET Imaging: Unexpected Findings in a Multicenter Clinical Pretrial Assessment.

Authors:  Dale L Bailey; Michael S Hofman; Nicholas J Forwood; Graeme J O'Keefe; Andrew M Scott; Winifred M van Wyngaardt; Bonnie Howe; Olga Kovacev; Roslyn J Francis
Journal:  J Nucl Med       Date:  2018-01-11       Impact factor: 10.057

3.  TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).

Authors:  Michael S Hofman; Louise Emmett; John Violet; Alison Y Zhang; Nicola J Lawrence; Martin Stockler; Roslyn J Francis; Amir Iravani; Scott Williams; Arun Azad; Andrew Martin; Margaret McJannett; Ian D Davis
Journal:  BJU Int       Date:  2019-10-22       Impact factor: 5.588

4.  The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study.

Authors:  Paul J Roach; Roslyn Francis; Louise Emmett; Edward Hsiao; Andrew Kneebone; George Hruby; Thomas Eade; Quoc A Nguyen; Benjamin D Thompson; Thomas Cusick; Michael McCarthy; Colin Tang; Bao Ho; Philip D Stricker; Andrew M Scott
Journal:  J Nucl Med       Date:  2017-06-23       Impact factor: 10.057

5.  PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study.

Authors:  Andrew M Scott; Dishan H Gunawardana; Ben Kelley; John G Stuckey; Amanda J Byrne; Jayne E Ramshaw; Michael J Fulham
Journal:  J Nucl Med       Date:  2008-08-14       Impact factor: 10.057

6.  The National Oncologic PET Registry (NOPR): design and analysis plan.

Authors:  Bruce E Hillner; Dawei Liu; R Edward Coleman; Anthony F Shields; Ilana F Gareen; Lucy Hanna; Sharon Hartson Stine; Barry A Siegel
Journal:  J Nucl Med       Date:  2007-10-17       Impact factor: 10.057

7.  Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.

Authors:  Michael S Hofman; Nathan Lawrentschuk; Roslyn J Francis; Colin Tang; Ian Vela; Paul Thomas; Natalie Rutherford; Jarad M Martin; Mark Frydenberg; Ramdave Shakher; Lih-Ming Wong; Kim Taubman; Sze Ting Lee; Edward Hsiao; Paul Roach; Michelle Nottage; Ian Kirkwood; Dickon Hayne; Emma Link; Petra Marusic; Anetta Matera; Alan Herschtal; Amir Iravani; Rodney J Hicks; Scott Williams; Declan G Murphy
Journal:  Lancet       Date:  2020-03-22       Impact factor: 79.321
  7 in total
  1 in total

1.  Global Advancement of Nuclear Medicine: KSNM 60 Years of Achievements.

Authors:  Andrew M Scott
Journal:  Nucl Med Mol Imaging       Date:  2021-05-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.